Diabetes, Vol 43, Issue 2 204-211, Copyright © 1994 by American Diabetes Association

ARTICLES

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys

JW Kemnitz, DF Elson, EB Roecker, ST Baum, RN Bergman and MD Meglasson
Wisconsin Regional Primate Research Center, Madison 53715-1299.

The antidiabetic effects of pioglitazone hydrochloride were evaluated in 6 spontaneously obese, insulin-resistant rhesus monkeys. The animals were studied during six successive 2-wk treatment phases separated by 2-wk rest periods: two placebo phases; 0.3, 1.0, and 3.0 mg.kg-1 x day-1 pioglitazone hydrochloride phases; and a final placebo phase. During the second week of each treatment phase, serum insulin (immunoreactive insulin [IRI]), plasma glucose, and serum triglyceride (TG) levels were measured after an overnight fast and after a standardized meal. Blood pressure was measured and glucose tolerance tests (modified minimal model protocol) were performed a few days after the meal tests. Pioglitazone hydrochloride significantly improved fasting and postprandial levels of IRI, plasma glucose, and TG in a dose-related manner (P < 0.05). Fasting values during treatment with 3.0 mg.kg-1 x day-1 were reduced by 64% for IRI, 19% for plasma glucose, and 44% for TG compared with the placebo phase before treatment. Efficacy of pioglitazone hydrochloride was more marked for those animals with fasting hyperglycemia. Insulin sensitivity was increased by pioglitazone hydrochloride (P = 0.05), whereas glucose effectiveness and glucose disappearance rate were not detectably affected. Systolic and mean arterial blood pressures were significantly decreased by pioglitazone hydrochloride (P < 0.05). No toxic side effects of pioglitazone hydrochloride treatment were noted.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. L. Christensen, B. Meibohm, E. V. Capparelli, P. Velasquez-Mieyer, G. A. Burghen, and W. V. Tamborlane Single- and Multiple-Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes J. Clin. Pharmacol., October 1, 2005; 45(10): 1137 - 1144. [Abstract] [Full Text] [PDF]

				H. K. Ortmeyer, Y. Adall, K. R. Marciani, A. Katsiaras, A. S. Ryan, N. L. Bodkin, and B. C. Hansen Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-{alpha} agonist (K-111) administration in rhesus monkeys Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1509 - R1517. [Abstract] [Full Text] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, M. Matsuda, and R. A. DeFronzo Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 517 - 523. [Abstract] [Full Text] [PDF]

				A. L. Hevener, D. Reichart, A. Janez, and J. Olefsky Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats Diabetes, October 1, 2001; 50(10): 2316 - 2322. [Abstract] [Full Text]

				Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone Diabetes Care, April 1, 2001; 24(4): 710 - 719. [Abstract] [Full Text]

				T. W. Kurtz and D. G. Gardner Transcription-Modulating Drugs : A New Frontier in the Treatment of Essential Hypertension Hypertension, September 1, 1998; 32(3): 380 - 386. [Abstract] [Full Text] [PDF]

				A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]

				T.-A. C. Tai, C. Jennermann, K. K. Brown, B. B. Oliver, M. A. MacGinnitie, W. O. Wilkison, H. R. Brown, J. M. Lehmann, S. A. Kliewer, D. C. Morris, et al. Activation of the Nuclear Receptor Peroxisome Proliferator-activated Receptor gamma Promotes Brown Adipocyte Differentiation J. Biol. Chem., November 22, 1996; 271(47): 29909 - 29914. [Abstract] [Full Text] [PDF]

				T. A. Kotchen Attenuation of Hypertension by Insulin-Sensitizing Agents Hypertension, August 1, 1996; 28(2): 219 - 223. [Full Text]

				W. R. Oliver Jr., J. L. Shenk, M. R. Snaith, C. S. Russell, K. D. Plunket, N. L. Bodkin, M. C. Lewis, D. A. Winegar, M. L. Sznaidman, M. H. Lambert, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport PNAS, April 24, 2001; 98(9): 5306 - 5311. [Abstract] [Full Text] [PDF]